Comment From Breakthrough Breast Cancer Suggesting Women Are Missing Out On Aromatase Inhibitors, UK
Main Category: Breast CancerAlso Included In: Cancer / Oncology
Article Date: 06 Oct 2008 - 2:00 PDT
| Patient / Public: | ![]() |
|
| Health Professional: | ![]() |
2 (1 votes) |
| Article Opinions: | 0 posts |
Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This research shows that the vast majority of breast cancer specialists surveyed were confident that patients in their breast units and who could benefit from Aromatase Inhibitors (AIs) were receiving them in line with NICE guidance. However, it's vital that this is backed up by formal audits to ensure that all patients receive the best treatments for them. "
"For many breast cancer patients, tamoxifen will be the most suitable treatment. However it's important to ensure that patients who may benefit from AIs are identified."
Breakthrough Breast Cancer
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add to:
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2008 MediLexicon International Ltd |





